Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3363182 | 0.80 | CYP3A4 (0.42) | CYP3A4TSHRALDH1A1GAAMAPT | |
| SCHEMBL1463893 | 0.77 | PARP1 (0.36) | KCNH2ALDH1A1HPGDMBOAT4NPSR1 | |
| SCHEMBL6193822 | 0.77 | SMN1; SMN2 (0.45) | CYP3A4TSHRKCNH2ALDH1A1HPGD | |
| SCHEMBL13680814 | 0.77 | KCNH2 (0.35) | KCNH2MAPTMBOAT4NPSR1PGK1 | |
| SCHEMBL28474866 | 0.75 | KCNH2 (0.40) | CYP3A4TSHRKCNH2ALDH1A1GAA | |
| SCHEMBL11904135 | 0.74 | KCNH2 (0.50) | CYP3A4TSHRKCNH2ALDH1A1GAA | |
| SCHEMBL1400836 | 0.74 | KCNH2 (0.39) | CYP3A4TSHRKCNH2ALDH1A1GAA | |
| SCHEMBL27672349 | 0.74 | KCNH2 (0.39) | CYP3A4TSHRKCNH2ALDH1A1GAA | |
| SCHEMBL30578990 | 0.74 | KCNH2 (0.39) | CYP3A4TSHRKCNH2ALDH1A1GAA | |
| SCHEMBL12720913 | 0.74 | HRH1 (0.47) | CYP3A4TSHRKCNH2ALDH1A1MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | BEYANG THERAPEUTICS CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4556466-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025082316-A1 | OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州必扬医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119604488-A | Protein tyrosine kinase inhibitor and medical application thereof | 苏州必扬医药科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2024032584-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | 苏州必扬医药科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049071-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | KDR, FLT1, ERBB2 | CYP3A4 4777/4885TSHR 687/4885KCNH2 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.